4TEEN4 Pharmaceuticals GmbH
4TEEN4 Pharmaceuticals GmbH is a German biotech company pioneering precision medicine in critical care, with a mission to develop causal therapies for acute cardiovascular complications, particularly shock. The company focuses on targeting cDPP3, a key mediator in circulatory failure, and is advancing Procizumab, a first-in-class antibody, through clinical development. With a leadership team boasting over 150 years of pharma experience and a strong network of international researchers, 4TEEN4 aims to address unmet medical needs and improve patient outcomes where current therapies are inadequate.
4TEEN4 Pharmaceuticals GmbH
Neuendorfstrasse 15A, 16761 Hennigsdorf, Germany
What We Do
A humanized monoclonal antibody that binds and inhibits cDPP3, restoring control over the RAAS system, normalizing cardiovascular function, reversing organ dysfunction, and increasing survival. Procizumab is in clinical development for the treatment of shock, with Phase 1 trials completed and further clinical studies planned.
A prognostic marker and major cause of circulatory failure, validated in over 100,000 patients. 4TEEN4 has developed and out-licensed the DPP3 biomarker for use in diagnostic platforms for prediction and monitoring of cardiogenic shock.
Digital Health Technologies
Application Area
Infectious Diseases
Routes of Administration
Key People
News & Updates
Awarded to Adrien Picod for research on cDPP3 in circulatory failure, in collaboration with 4TEEN4.
Awarded to Florian A. Wenzl, MD, for research identifying cDPP3 as a biomarker of cardiogenic shock.
Coverage of 4TEEN4's new therapy for heart attack patients.
Article discussing 4TEEN4's approach to shock treatment.
Feature on 4TEEN4's innovative work in cardiovascular disease.
4TEEN4 successfully completed its Phase 1 clinical trial for Procizumab, confirming a favorable safety profile and preparing for further clinical trials in circulatory failure.